Academic Bibliography

Search 200 years of publications by Ghent University researchers.

Mérédis Favreau

Email: Meredis.Favreau@UGent.be

Show Sort by

Mark
- journalArticle
- A1
- open access
Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition

Mérédis Favreau (UGent) , Koen Venken (UGent) , Sylvia Faict, Ken Maes, Kim De Veirman, Elke De Bruyne, Xavier Leleu, Louis Boon, Dirk Elewaut (UGent) , Karin Vanderkerken, et al.

(2017) HAEMATOLOGICA. 102(7). p.E266-E270
Mark
Leptin receptor antagonism of iNKT cell function : a novel strategy to combat multiple myeloma

Mérédis Favreau (UGent) , E Menu, Djoere Gaublomme (UGent) , K Vanderkerken, S Faict, K Maes, E De Bruyne, Srinath Govindarajan (UGent) , Michael Drennan (UGent) , Serge Van Calenbergh (UGent) , et al.

(2017) LEUKEMIA. 31(12). p.2678-2685
Mark
- dissertation
Immune therapy in multiple myeloma : can iNKT cells be targeted?

Mérédis Favreau (UGent)

(2017)
Mark
- journalArticle
- A1
- open access
Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells

Nathan De Beule, Eline Menu, Mathieu Bertrand (UGent) , Mérédis Favreau (UGent) , Elke De Bruyne, Ken Maes, Kim De Veirman, Magdalena Radwanska (UGent) , Afshin Samali, Stefan Magez (UGent) , et al.

(2017) ONCOTARGET. 8(32). p.52016-52025
Mark
- journalArticle
- A1
- open access
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?

Mérédis Favreau (UGent) , Karin Vanderkerken, Dirk Elewaut (UGent) , Koen Venken (UGent) and Eline Menu

(2016) ONCOTARGET. 7(17). p.23128-23140
Mark
- journalArticle
- A1
- open access
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model

Haneen Nur, Karel Fostier, SANDRINE ASPESLAGH (UGent) , Wim Renmans, Elisabeth Bertrand, Xavier Leleu, Mérédis Favreau (UGent) , Karine Breckpot, Rik Schots, Marc De Waele, et al.

(2013) PLOS ONE. 8(5).